Zacks Investment Research
01 Oct 2026, 14:55 UTC · 1h ago
Verdict
Headline takes no side. We score MRK +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Merck announced that the phase IIb MK-7240-012 study for tulisokibart in patients with moderate to severe hidradenitis suppurativa met its primary endpoint.
Newannounced October 01, 2026
So whatSuccess in this trial paves the way for Phase III development, which typically takes 2-4 years before potential FDA filing.
More positive than 93% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
High-dose (480 mg every two weeks) and medium-dose (480 mg every four weeks) tulisokibart achieved HiSCR50 rates of 72% and 64%, respectively, versus 35% for placebo.
Newannounced October 01, 2026
So whatThe high-dose efficacy is 37 percentage points higher than placebo, supporting a strong competitive profile for future market entry.
More positive than 87% of claims this week
Tulisokibart demonstrated HiSCR75 response rates of 41% for high-dose and 40% for medium-dose compared to 15% for placebo.
Newannounced October 01, 2026
So whatStronger HiSCR75 responses often correlate with higher pricing power and better formulary placement upon commercialization.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
Phase IIb study for tulisokibart met its primary endpoint with positive results, and the drug will advance to phase III.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
9h ago
−0.3%
Price flat so far
$144.88 vs $145.31 close before publication (Sep 30) · not market-adjusted
MRK chart →
